Actavis pipeline is flowing
November 16, 2012
OVER the next 12 months Ascent
and Willow Pharmaceuticals
customers can expect a large
number of new products, following
the recent Watson acquisition of
Activis.
“As the world's third largest
generic pharmaceutical business,
the company to be known as
Actavis, has an industry leading
global product portfolio of over 750
molecules offered in more than
1,700 different combinations and
dosage forms,” the company said in
a statement.
According to the company, its
current pipeline includes more than
2,000 marketing authorisations
pending approval and, globally,
greater than 600 new development
projects are underway covering
multiple dosage forms.
Speaking in the wake of the
acquisition, Karen McTavish,
Managing Director of Watson
Australia said “This year has been
tough, and we have worked hard at
keeping profits up for our Ascent
Generic customers”.
“This acquisition will allow us to
increase our product portfolio in a
short time frame, including first to
markets with better margins.
“Beyond products and price we
are even better placed to offer
pharmacies unique programs and
tools proven to work in other
markets that will increase
pharmacy customer engagement
and in turn benefit the overall
pharmacy offering,” she added.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Nov 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Nov 12
